Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brian Hunter

Physician Assistant Harold, KY Physician Assistant

NPI 1811976616 CMS profile 10975769

24 Left Penhook Rd, Harold, KY 41635

Open in the dashboard

General payments

$5,569

330 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Hunter of Harold, KY is reported in the CMS Open Payments database as having received $5,569 across 330 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,001 50
2024 General $1,296 65
2023 General $718 41
2022 General $1,220 80
2021 General $1,334 94

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Hunter
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Brian Hunter were reported at $1,001. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Brian Hunter Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,334 $132 $37–$438 $132
2022 $1,220 $155 $48–$522 $149
2023 $718 $167 $52–$557 $160
2024 $1,296 $178 $55–$600 $164
2025 $1,001 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $978 61 payments
  2. Novartis Pharmaceuticals Corporation $602 32 payments
  3. GlaxoSmithKline, LLC. $551 34 payments
  4. AstraZeneca Pharmaceuticals LP $546 17 payments
  5. Pfizer Inc. $439 28 payments
  6. Lilly USA, LLC $429 32 payments
  7. Sanofi-Aventis U.S. LLC $354 22 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $246 15 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $240 16 payments
  10. Biohaven Pharmaceuticals, Inc. $226 14 payments
  11. Other $957 59 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,569 330 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $734 46 payments
  2. LEQVIO $586 31 payments
  3. TRELEGY ELLIPTA $533 33 payments
  4. NURTEC ODT Primary Care $465 30 payments
  5. AIRSUPRA $441 10 payments
  6. FARXIGA $392 9 payments
  7. NURTEC ODT Pain $390 25 payments
  8. ZAVZPRET $325 20 payments
  9. QULIPTA $323 17 payments
  10. SOLIQUA 100/33 $315 20 payments
  11. Other $2,620 170 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 196 drugs

Part D claims

14,218

Median for Physician Assistant: 241

Drug cost

$2,011,089

Median for Physician Assistant: $4,110

Branded share of claims

25.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 461 $488,755
Leqvio Inclisiran Sodium Brand 87 $281,139
Farxiga Dapagliflozin Propanediol Brand 210 $135,973
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 157 $103,336
Jardiance Empagliflozin Brand 102 $88,979
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 84 $75,773
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 92 $68,080
Eliquis Apixaban Brand 67 $54,718
Linzess Linaclotide Brand 90 $52,097
Litfulo Ritlecitinib Tosylate Brand 13 $51,321

The 10 drugs with the highest cost, of 196 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $227
$227 87 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $174
$174 210 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $116
$116 — —
UBRELVY
  • AbbVie, Inc. $100
$100 20 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $100
$100 92 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

330 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record